Aditi Ashok misses medal narrowly, ends 4th at Olympics
Tokyo: India's Aditi Ashok missed a medal narrowly as she signed off 4th in the Olympic Games' golf competition after carding a three-under 68 in the weather-hit final round here on Saturday.
The 23-year-old Bengalurean ended two strokes off the pace with a total of 15-under 269.
It was a heartbreaking end to Aditi's campaign considering she started the day at 2nd. But it was nonetheless a major improvement as she had finished tied 41st in the 2016 edition where golf made a comeback to the Olympics.
In the final round, she fired five birdies -- on the 5th, 6th, 8th, 13th and 14th holes -- against two bogeys on the 9th and 11th.
Overnight leader and world number one Nelly Korda clinched the gold medal with a 2-under 69 that left her 17-under overall and a shot ahead of Japan's Mone Inami (65) and New Zealand's Lydia Ko (65).
Inami and Ko will compete in a play-off to decide the silver and bronze medal winners.
Play was disrupted for a while by a tropical storm after the leading pack had completed 16 holes but soon resumed at the par-71 Kasumigaseki Country Club.
Aditi was in medal contention for a major part of the day but the two bogeys pulled her back while Ko surged ahead with a sensational nine birdies against just three dropped shots in her final round.
Let the Truth be known. If you read VB and like VB, please be a VB Supporter and Help us deliver the Truth to one and all.
Ballari maternal deaths: Karnataka govt. seeks explanation from CDSCO
Bengaluru: The Karnataka Government has sought clarification from the Central drugs standard control organisation following reports linking the serial deaths of pregnant women at Ballari District Hospital to unsafe IV Ringer's Lactate solution. Health Department Principal Secretary Harsha Gupta has written a letter to the Drugs Controller General of India, Rajeev Singh Raghuvanshi.
Recent Investigations revealed bacterial and fungal contaminants in the IV solution given to the women. Out of 192 batches supplied by a West Bengal-based pharmaceutical company, 22 were found substandard by the state drug control department, leading to the suspension of the medicine's use.
However, these batches had passed quality tests at the Central Drug Lab, creating a regulatory conflict.
The Health Department emphasized adherence to tender rules, stating that the Central Drug Lab's approval is legally binding. Samples from the problematic batches have been sent for re-testing at the central lab in West Bengal, with results expected on December 9.
As a precautionary measure, the state has blacklisted the implicated batches and issued directives to halt their use in all hospitals.
